Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.

Gunther, R

Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. [electronic resource] - Blood May 1995 - 2537-45 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

0006-4971


Animals
Antibodies, Monoclonal--administration & dosage
Antigens, CD--immunology
Antigens, CD19
Antigens, Differentiation, B-Lymphocyte--immunology
Blood-Brain Barrier
Bone Marrow--pathology
Cell Movement
Central Nervous System--pathology
DNA, Neoplasm--analysis
Drug Evaluation, Preclinical
Immunotoxins--administration & dosage
Injections, Intraperitoneal
Injections, Intravenous
Injections, Spinal
Leukemic Infiltration--drug therapy
Meninges--pathology
Methotrexate--therapeutic use
Mice
Mice, SCID
N-Glycosyl Hydrolases
Neoplasm Transplantation
Neoplastic Cells, Circulating
Plant Proteins--administration & dosage
Polymerase Chain Reaction
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma--drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy
Ribosome Inactivating Proteins, Type 1
Specific Pathogen-Free Organisms
Transplantation, Heterologous